Pfizer Inc.

Strong Financial Performance: Pfizer reported a full-year revenue of $63.6 billion for 2024, an increase from $59.6 billion in 2023. Adjusted diluted earnings per share rose to $3.11, up from $1.84 year-over-year, significantly exceeding expectations. This growth was primarily driven by solid sales of non-COVID-19 products, which saw an operational revenue growth of 12%.

Forward Guidance for 2025: For full-year 2025, Pfizer anticipates total revenues in the range of $61 billion to $64 billion and adjusted diluted EPS between $2.80 and $3.00. This reflects strong contributions expected from various product portfolios while managing a projected $1 billion revenue net headwind from the IRA Medicare Part D redesign.

R&D Productivity Focus: Pfizer is shifting its strategic emphasis towards improving R&D productivity in 2025 with a robust pipeline anticipated to deliver multiple key milestones, including potential regulatory decisions and Phase 3 readouts. This includes a strong focus on oncology and vaccines, which are expected to drive future growth.